[Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
The GLP-1-receptor-agonist liraglutide (Victoza) has been approved for the treatment of diabetes mellitus type 2 in Europe. Liraglutide is the first human GLP-1 analogue which is applied once a day. Efficacy and safety of liraglutide were investigated in the broad LEAD-study-programme in comparison with placebo and other common therapeutics for the treatment of diabetes mellitus type 2. Liraglutide has been approved for the combination with metformin and/or a sulfonylurea or with metformin and a thiazolidinedione, if treatment with one or a combination of these drugs is not sufficient for an adequate blood glucose control.
Jahn
Ellen
E
ellen.jahn@t-online.de
Sausele
Tanja
T
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D052216:Glucagon-Like Peptide 1 / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069450:Liraglutide; D008687:Metformin / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D008687:Metformin